Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2010

View Archived Issues

Enrollment progresses in phase IIb vidofludimus trial in rheumatoid arthritis

Capsaicin-mediated TRPV1 activation may help battle hypertension

Researchers describe new mPTP inhibitors

Aviptadil does not improve pulmonary vascular resistance in phase II trial in PAH

Polymorphic variants in HTR2A gene may predict extent of musculoskeletal pain

Agenix progresses preclinical development of hepatitis B drug AGX-1009

Addex raises funds to further develop ADX-48621

Wintherix elects WX-04554 as lead drug for bone healing

FDA accepts Eisai's NDA for Aricept transdermal patch for review

FDA committee recommends approval of Vivitrol for opioid dependence

VX-770 shows promise in patients with cystic fibrosis

FDA advisory committee does not recommend approval of lorcaserin for obesity

Merck & Co. identifies new glucagon receptor antagonists

Janssen Pharmaceutica claims new phosphodiesterase 10A ligands

FDA awards grant to AGTC for phase II trial in Leber's congenital amaurosis

Prometheus and Tarrot Laboratories to identify biomarkers of response to anti-TNF drugs for CD

New York University discloses novel antibacterial agents

Genfit advances GFT-505 to phase II in type 2 diabetes

BioCryst Pharmaceuticals' BCX-4208 shows efficacy in gout

Urifer claims new heterocyclic compound for cancer therapy

Galderma discloses new ACAT-1 inhibitors

ISTA initiates two studies in phase III program for Remura in dry eye disease

European and U.S. regulatory submissions planned for Zolmitriptan RapidFilm

Oramed Pharma reports data from exploratory study of oral insulin capsule

Phase II trial begins for SG-2000 in ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...